Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Sinogen Biopharma
AddedFeb 15, 2024
UpdatedJun 18, 2026
Sinogen Biopharma

Sinogen Biopharma

Series B

Sinogen Biopharma: Bridging China's biotech innovation to the US via innovative drug development.

HQ
Boston, MA, US
Founded
2016
Overview
Compare
Fundraising
Employees

Sinogen Biopharma is dedicated to bridging China's biotech innovation with the US pharmaceutical market. The company focuses on licensing and developing innovative drugs from China, aiming to bring advanced therapeutic solutions to a broader audience.

Sinogen Biopharma has made significant strides in drug development, contributing to the global pharmaceutical landscape. The company's efforts have facilitated the introduction of cutting-edge treatments, enhancing healthcare outcomes and fostering international collaboration in biotech innovation.

Sinogen Biopharma - Similar Companies

Sino Biopharmaceutical logo

Sino Biopharmaceutical

Denovo Biopharma logo

Denovo Biopharma

Endogenx logo

Endogenx

BridGene Biosciences logo

BridGene Biosciences

Bionpharma logo

Bionpharma

bionpharma.com

Kyntra Bio logo

Kyntra Bio

fibrogen.com

BridgeBio Pharma logo

BridgeBio Pharma

bridgebio.com

Brii Biosciences logo

Brii Biosciences

briibio.com

CinRx Pharma logo

CinRx Pharma

cinrx.com

Sinapis Pharma logo

Sinapis Pharma

Signet Therapeutics logo

Signet Therapeutics

BiotechInnova logo

BiotechInnova

biotechinnova.com

Ziran Biopharmaceutical logo

Ziran Biopharmaceutical

BioPro Pharmaceutical logo

BioPro Pharmaceutical

Goldfinch Bio logo

Goldfinch Bio

Sinogen Biopharma - Quick Facts

Who are Sinogen Biopharma's competitors?

Companies similar to Sinogen Biopharma include Sino Biopharmaceutical, Denovo Biopharma, Endogenx and BridGene Biosciences.

When was Sinogen Biopharma founded?

Sinogen Biopharma was founded in 2016.

Where is Sinogen Biopharma's headquarters located?

Sinogen Biopharma's headquarters is located in Boston, MA, US.

How much has Sinogen Biopharma raised to-date?

As of Dec 31, 2023, Sinogen Biopharma has raised a total of $13M (USD).

How many employees does Sinogen Biopharma have?

Sinogen Biopharma has 6 employees as of Feb 4, 2024.

Sinogen Biopharma - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Development
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 12 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research